Not all of drug innovations are created equal. Some aren’t better than existing standards of care. Others are breakthroughs. Still others are marginal improvements.
Category: pharma & healthcare
Pain, Pain Go Away: New Non-Addictive Painkiller Shows Promise In Early Trials
A novel class of non-addictive painkillers may be just around the corner, offering a much-needed alternative to opioids.
Building The Brain-Machine Connection: Deciphering Thoughts For Action
New cortical brain-machine interface technologies will soon aid those with brain injury or neurodegenerative diseases to improve basic motor function.
A Different Kind Of Cancer Killer: Improving CAR NK Cell Therapy
One study discovers why CAR NK cells lose steam over time and suggests a way to rejuvenate their cancer-killing ability.
Kim Kardashian’s Promotion Of Full-Body Scans Raises Questions About Social Media Influence In Healthcare
Whichever drug or diagnostic, consumers and patients should be looking to learned intermediaries, such as their doctors, for health advice and not celebrity influencers.
Rejuvenating Old Brains: Platelet Factor 4 (PF4)
As we age, so does our brain. There’s no way around it. Or is there? New research has identified a small protein that seemingly returns youth to aging brains.
Inflation Reduction Act May Accelerate Generic And Biosimilar Market Entry, But Questions Remain Around CMS Guidance
The IRA may alter the incentives drug firms have to pursue evergreening strategies, as having generic or biosimilar competition can exempt a drug from price negotiation.
Can We Turn Back The Clock? Parabiosis Research Suggests Yes
Aging is considered a given; a natural and inevitable part of life. Researchers at Harvard Medical School are pushing back. Age, their work suggests, may be reversible.
CMS Faces Major Challenges As It Establishes Itself As A Health Technology Assessment Entity In The Wake Of The IRA
As CMS establishes itself as an HTA entity, it may consider carving out the HTA function and delegating it to an external entity that can operate as a neutral arbiter.
The List Of 10 Drugs Medicare Will Negotiate Prices Of Contains A Few Surprises
Conspicuously, CMS included drugs that could face imminent generic or biosimilar competition before 2026, which is when the negotiated prices first go into effect.
